You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(688505.SH):注射用FZ-P001鈉用於癌症術中惡性病變可視化獲得藥物臨牀試驗申請受理通知書

格隆匯6月16日丨復旦張江(688505.SH)公佈,公司於近日收到國家藥品監督管理局覈準簽發的《受理通知書》,注射用FZ-P001鈉(以下簡稱“該藥物”)用於癌症術中惡性病變可視化的I期臨牀試驗申請獲得受理。

注射用FZ-P001鈉爲本公司自主研發的化學藥品1類新化合物,是一種創新型光敏劑,其活性成分爲葉酸受體靶向小分子與花菁類光敏劑偶聯而成的分子,可靶向葉酸受體α(FRα)高表達的惡性腫瘤組織並在近紅外區間熒光顯影。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account